Compiled June 2025 | Targeting permanent, one-time or short-course interventions
Alpha-gal syndrome (AGS) is a tick bite-induced IgE-mediated allergy to the carbohydrate epitope galactose-α-1,3-galactose (α-Gal), found in virtually all non-primate mammals. Humans lost the GGTA1 gene encoding α-1,3-galactosyltransferase approximately 20–28 million years ago, so α-gal is foreign to us at a deep evolutionary level — we naturally produce anti-Gal IgM and IgG comprising ~1% of circulating immunoglobulins driven by gut bacterial antigens. When a tick bite delivers α-gal in a Th2-inflammatory context, the isotype switch to IgE occurs, triggering the syndrome.
This creates a paradox for curative approaches: the immune system was designed to recognize α-gal. Any cure must therefore override a deeply phylogenetically conserved immune response. But AGS is also, unusually among allergies, one that can naturally wane. The Commins et al. natural history study showed that 89% of patients who avoided re-exposure to tick bites experienced a significant decline in α-gal sIgE (median ~27% per year), and roughly 12% of patients tracked >5 years had negative titers and were able to reintroduce mammalian meat. That spontaneous, tick-avoidance-driven resolution is itself a form of "cure" — and it establishes that the pathogenic IgE is not permanently locked in. The curative mechanisms below are all attempts to replicate, accelerate, or supersede that natural process, with varying degrees of scientific ambition.
Chimeric antigen receptor regulatory T cells (CAR-Tregs) are Foxp3+ regulatory T cells engineered to express a CAR that homes them to specific tissues or antigens, where they deliver potent bystander immunosuppression. Naturally occurring Tregs are critical for oral and mucosal tolerance — their failure underlies food allergy sensitization, and their restoration correlates with clinical tolerance after oral immunotherapy. The theory for AGS is direct: engineer Tregs with a CAR that recognizes α-gal or the tissue context of α-gal exposure (gut, mast cell surfaces) and have them suppress the local effector arm — Th2 cells, IgE-producing B cells, mast cells, and basophils.
Two major platforms exist. Allergen-specific CAR design would target an α-gal-conjugated scaffold (since α-gal is a carbohydrate and can be chemically linked to protein anchors or membrane scaffolds); the CAR would recognizes the α-gal epitope expressed on cell surfaces or conjugated to an antigen. Alternatively, a tissue-targeting CAR (like Sangamo's IL-23R approach for Crohn's disease) could localize Tregs to the gut where alpha-gal-loaded mast cells and basophils reside, driving bystander suppression non-specifically but durably. A third angle: a CD19 CAR-Treg (like Quell's QEL-005) would suppress B cell activity broadly in tissues, reducing the B cell population responsible for class-switching to IgE.
The mechanism of suppression is multifactorial: Tregs release IL-10, TGF-β, and IL-35; express CTLA-4 and PD-L1 to shut down co-stimulation; deplete IL-2 via CD25; and directly inhibit mast cell degranulation. A 2013 review in JACI established that allergen-specific Tregs can block the very Th2 cell responses needed for IgE class switching — if delivered before sensitization, or at high enough levels, they could interrupt the cycle.
Quell Therapeutics has the most advanced CAR-Treg clinical program relevant to this pathway. Their lead asset QEL-001 is in Phase 1/2 LIBERATE trial in liver transplant patients, with published data showing trafficking, engraftment, and 6-month cell persistence — a critical proof of principle. Their CHILL trial (Phase 1/2) initiated in March 2026 tests QEL-005, a CD19 CAR-Treg for rheumatoid arthritis and systemic sclerosis, specifically designed to suppress B cells and thereby autoantibody production.
Sangamo Therapeutics is in Phase 1/2 STEADFAST trial with TX200, an HLA-A2-specific CAR-Treg for kidney transplantation. Their August 2025 update confirmed no safety signals in 8 patients and evidence of CAR-Treg engraftment in kidney biopsies — a stunning proof that these cells can home, survive, and not cause immune chaos. Sonoma Biotherapeutics presented Phase 1 interim data at ACR 2025 on autologous CAR-Tregs in refractory rheumatoid arthritis.
No program has yet tested a CAR-Treg in food allergy or AGS specifically. The PMC review on Tregs in allergic disease (2024) notes the compelling preclinical rationale but absence of allergen-targeted clinical programs.
The manufacturing is currently autologous (patient's own T cells, extracted, modified, expanded, re-infused) — complex, expensive (~$500K+/patient currently), and logistically demanding. Allogeneic "off-the-shelf" CAR-Tregs would be transformative and are in early development. For AGS specifically, the target definition is the hardest problem: α-gal is a carbohydrate, not easily presented by MHC in the conventional sense. Designing a CAR that recognizes free α-gal or α-gal-conjugated cell surface structures at the relevant effector sites requires significant engineering work not currently underway.
- Carbohydrate CAR design: Standard CARs use scFv antibody fragments that bind protein epitopes. Carbohydrate-recognizing antibodies with sufficient affinity are rarer; a lectin-based CAR domain would be needed, with unknown on-target/off-target profile.
- Transient suppression: If CAR-Tregs home to an area depleted of α-gal (because patient is on elimination diet), they may not get the antigen signal to remain activated and could lose function.
- Th2 environment undermines Treg function: In established allergy, the IL-4/IL-13 milieu can reprogram Foxp3+ Tregs toward a Th2 phenotype, a phenomenon documented in food allergy patients per the 2025 Frontiers in Immunology T-cell tolerance review.
- Cost and scale: Until allogeneic platforms mature, this cannot be a population-level solution.
The key insight here is anatomical: in IgE-mediated allergy, a relatively small pool of B cells has undergone class switch recombination to produce IgE. These IgE-expressing B cells carry membrane-bound IgE (mIgE) as their B cell receptor, and this mIgE isoform is expressed only on cells of the IgE lineage — not on B cells producing IgG, IgA, or IgM. The mIgE molecule has a unique extracellular domain (CεmX) not present on secreted IgE or other isotypes. This presents a targetable structure: a CAR-T cell or engineered antibody that binds CεmX can selectively eliminate the IgE-producing B cell compartment while leaving the broader immune system intact, without the hypogammaglobulinemia that results from pan-B cell depletion.
If the IgE B cell pool is eliminated, circulating IgE half-life is ~2–3 days, so serum IgE would drop precipitously. Mast cells and basophils coated with IgE would gradually lose their surface receptor loading. This could achieve a functional cure — not by restoring tolerance, but by removing the effector antibody and its cellular source entirely.
MEDI4212 (MedImmune/AstraZeneca): A seminal 2015 study in PMC/Journal of Allergy demonstrated engineered anti-IgE antibodies with enhanced Fc effector function (ADCC) that could both neutralize soluble IgE and kill IgE-expressing B cells in cell-based assays. MEDI4212 showed enhanced affinity for FcγRIIIa and was described as capable of eliminating class-switched IgE B cells in vitro, potentially preventing their differentiation into IgE-secreting plasma cells. This program did not advance to clinical trials, but it established the conceptual framework.
Anti-CεmX approach: A 2012 PubMed study characterized antibodies targeting the CεmX/migis junctional region of mIgE, confirming selective binding to mIgE-expressing B cells with ADCC activity and reduction of IgE production without binding secreted IgE or other B cell isotypes. This epitope remains the gold standard target for IgE B cell depletion.
mIgE-targeted CAR-T cells: A 2023 review in PMC on CAR-T for atopic allergic diseases describes the development of EMPD CAR and ACED CAR designs targeting transmembrane IgE. The authors argue that mIgE-targeted CAR-T cells represent a potentially curative, single-infusion approach to all atopic allergic diseases — specifically because the target is disease-specific (only on IgE B cells), the approach is disease-modifying rather than symptom-reducing, and CAR-T cells can persist for >10 years.
Cabaletta Bio (rese-cel, resecabtagene autoleucel): While targeting CD19 (all B cells), Cabaletta's RESET program provides critical safety data. In October 2025, Fierce Biotech reported that Cabaletta achieved complete peripheral B cell depletion in autoimmune disease patients without preconditioning chemotherapy — a landmark result proving B cell-depleting CAR-T therapy can be simplified and de-risked. For an mIgE-specific CAR-T, the safety profile would be even more favorable given the narrower target population.
The CεmX/mIgE target is exceptionally well-validated. The primary unknowns are: (1) whether CAR-T or engineered antibody approaches can sufficiently eliminate IgE B cells from tissue-resident niches (lymph nodes, bone marrow) not just from circulation; and (2) whether residual long-lived IgE plasma cells (which have lost mIgE expression) would continue to secrete IgE even after B cell precursors are eliminated. The latter is a critical failure mode — long-lived plasma cells in bone marrow niches can persist and secrete antibody independent of B cell input, potentially for years. This is why even after HSCT, IgE can persist in some patients.
- Plasma cell escape: IgE-producing plasma cells lose mIgE expression and become invisible to mIgE-targeted therapies. Separate targeting of IgE plasma cells (e.g., with anti-CD38 or anti-BCMA in combination) would be required.
- Re-sensitization: Unless tick re-exposure is also prevented, newly emerging naive B cells could re-class-switch to IgE in a susceptible individual, reconstituting the disease.
- Carbohydrate allergen uniqueness: Most mIgE-targeting approaches have been designed/tested in protein allergy models. The carbohydrate nature of α-gal may affect the B cell receptor structure, clonal diversity, and whether the IGHV3-7 / W33 motif dominance described in PNAS 2022 affects CAR engagement.
- No clinical program for allergy yet: No company is currently running clinical trials of mIgE-targeted CAR-T in food allergy.
The classical approach to food allergy tolerance is oral immunotherapy (OIT) — repeated antigen exposure to desensitize. But OIT achieves desensitization, not necessarily durable tolerance, and can only be maintained with ongoing dosing. A true tolerogenic vaccine would present α-gal antigen in a context that actively programs the immune system toward tolerance: expanding antigen-specific Tregs, inducing anergy in pathogenic Th2 cells, and promoting IgG4 class switching while suppressing IgE.
The key element is the tolerogenic context. Rapamycin (an mTOR inhibitor) is uniquely suited: by blocking T cell effector differentiation while preserving Treg function, co-administration of antigen with rapamycin selectively tolerizes the responding T cell pool. The liver sinusoidal endothelial cell (LSEC) route is particularly potent — LSECs express MHC-II, absorb blood-borne antigens, but lack the co-stimulatory molecules needed to activate effector T cells; they instead present antigen in a manner that drives CD4+ Treg expansion and T cell anergy.
For AGS specifically: α-gal glycoproteins are the antigen; rapamycin-loaded nanoparticles or liver-targeting nanoparticle conjugates carrying α-gal epitopes could, in principle, drive clonal deletion or anergy of pathogenic Th2 cells and induce Tregs specific for α-gal.
Topas Therapeutics (Hamburg): Their liver-targeting nanoparticle platform (TPC — Topas Particle Conjugates) achieved Phase 2a proof-of-concept in celiac disease. In October 2024, Topas announced positive topline results showing statistically significant dose-dependent reduction of IL-2/IFN-γ release by gluten-specific T cells, persistent phenotypic changes in gliadin-specific T cells, and induction of gluten-specific regulatory CD4+ T cells. Full data presented at DDW May 2025 confirmed durable tolerance induction — the first clinical proof of concept that a tolerogenic nanoparticle vaccine can reprogram T cell responses to a dietary antigen in humans. This is directly relevant to AGS: α-gal is also a dietary antigen (in red meat), and the platform can in principle accommodate carbohydrate-conjugated peptide epitopes.
Selecta Biosciences / ImmTOR: Their SVP-Rapamycin (synthetic vaccine particles encapsulating rapamycin) platform has shown robust antigen-specific tolerance induction in multiple animal models, including prevention of anti-drug antibody formation, allergy models, and AAV gene therapy re-dosing. They have not advanced to food allergy clinical trials but preclinical peanut allergy data from 2017 showed the ability to inhibit peanut-specific IgE and prevent anaphylaxis in sensitized mice.
University of Michigan α-gal nanoparticles: A 2024 study in Frontiers in Allergy specifically applied biodegradable nanoparticles (PLG) loaded with α-gal glycoprotein to alpha-gal-knockout mice. Both prophylactic and therapeutic administration reduced Th2 cytokines (IL-4, IL-5, IL-13), α-gal-specific IgE, basophil activation, and mast cell reactivity. Prophylactic administration also increased IL-10, consistent with Treg induction. This is the most directly relevant animal study of a tolerogenic nanoparticle approach for AGS.
ImmusanT (Nexvax2): This tolerogenic peptide vaccine for celiac disease (HLA-DQ2.5-restricted gluten peptides) failed its Phase 2 primary efficacy endpoint. The company's experience is a cautionary tale: immune unresponsiveness to the peptides was demonstrated (reduced IL-2 release), but this did not translate to clinical benefit on gluten challenge, suggesting that T cell anergy alone may be insufficient when IgE effector pathways are already established.
COUR Pharmaceuticals: Tolerogenic nanoparticles for multiple autoimmune and allergic conditions. Their CNP-201 for peanut allergy entered first-in-human dosing in 2021, with results awaited.
The Topas Phase 2a data represent a genuine paradigm shift — it is now proven in humans that liver-targeting nanoparticle conjugates can induce antigen-specific T cell tolerance to a dietary antigen. The path to AGS application requires: (1) conjugation chemistry for the carbohydrate α-gal epitope (more challenging than peptides); (2) demonstration that the tolerized T cells can block the IgE arm of the response; (3) preclinical studies in the GGTA1 knockout pig model (the new gold-standard model per the 2024 Front. Immunol. paper). A Phase 1 trial for AGS is potentially achievable within 5–7 years if a company decides to pursue this indication.
- Carbohydrate antigen conjugation: Unlike peptide-based tolerogenic vaccines, α-gal is a sugar and must be conjugated to a carrier scaffold. The T cell component of the response is protein-dependent; pure carbohydrate presentation may not adequately engage the T cell tolerance pathway.
- Existing IgE memory: Tolerogenic T cell induction does not directly eliminate existing IgE memory B cells or long-lived plasma cells. The allergy might be suppressed but not erased.
- Tick re-exposure: A single tick bite after successful tolerogenic vaccination could break tolerance by re-providing the inflammatory co-stimulus that originally drove sensitization.
- HLA restriction: Some tolerogenic peptide approaches require specific HLA haplotypes (as with ImmusanT's DQ2.5 restriction). Carbohydrate-targeting would be HLA-independent, which is an advantage.
This mechanism is more accurately described as "preventing the disease from being maintained" rather than curing established AGS. The alpha-gal sensitization pathway requires a specific immunological context: tick saliva contains not just α-gal but also Th2-skewing factors (prostaglandin E2, IL-10, histamine-binding proteins) that simultaneously deliver α-gal and instruct the immune system to respond to it with an IgE response rather than a tolerogenic one. Without this inflammatory context, repeated α-gal exposure through diet actually promotes tolerance (since gut bacteria expressing α-gal continuously stimulate anti-Gal IgM/IgG without triggering AGS in non-sensitized individuals).
An anti-tick vaccine would work by causing vaccinated individuals to develop immune responses against tick salivary proteins. When a tick begins feeding, the host immune response would recognize tick antigens and generate skin responses that cause the tick to detach prematurely — before it has deposited the volume of α-gal-laden saliva needed for sensitization/re-sensitization. For existing AGS patients, an anti-tick vaccine cannot cure the allergy, but combined with tick avoidance, it could accelerate the natural IgE decline (~27%/year) by ensuring that re-sensitization events do not occur.
Fikrig/Gomes-Solecki 19ISP mRNA vaccine (Science Translational Medicine 2021): This Yale University-led study tested an mRNA vaccine encoding 19 Ixodes scapularis salivary proteins, delivered in lipid nanoparticles, in guinea pigs. Vaccinated animals developed erythema at tick attachment sites early in the feeding process, causing ticks to detach prematurely with reduced engorgement weights. This early detachment significantly impeded transmission of Borrelia burgdorferi (Lyme disease). The principle is that accelerated local immune responses effectively create "tick-resistant" animals. While the study focused on pathogen transmission, the mechanism — early tick detachment before full salivary delivery — would similarly reduce α-gal delivery.
Hart IscREAM 2025 (Science Translational Medicine 2025): A comprehensive profiling study using the I. scapularis rapid extracellular antigen monitoring (IscREAM) platform identified 199 tick antigens recognized by the host immune response across human and animal subjects. The study confirmed that vaccination with cement antigens induces acquired tick resistance and that a naturally tick-resistant human individual showed broad IgG responses to the exoproteome. This foundational antigen atlas informs next-generation multi-antigen anti-tick vaccines far more potent than 19ISP.
A clinical trial of tick-bite prevention vaccine is being considered by several groups; Pfizer has licensed anti-tick vaccine technology from Yale. The FDA has designated tick vaccines as a public health priority. A 2025 Nature Medicine commentary noted that tick vaccines could reduce the incidence of multiple tick-borne diseases simultaneously.
The combination of LNP-mRNA technology (now proven at scale), existing animal efficacy data, and clear public health rationale makes an anti-tick vaccine the most near-term developable intervention on this list. It would not cure existing AGS, but for newly diagnosed or mildly affected patients still in tick-endemic areas, it would be transformative. An anti-tick vaccine combined with tick avoidance could reduce re-sensitization to near zero, accelerating the natural IgE decline that the natural history data already confirm.
- Does not treat established allergy: Patients with high α-gal IgE titers still have existing sensitization; the vaccine only affects future sensitization events.
- Tick species specificity: 19ISP is specific to Ixodes scapularis (Northeastern US); patients sensitized by Amblyomma americanum (Lone Star tick), Ixodes ricinus (Europe), or Haemaphysalis longicornis (Asia) would require separately validated vaccine compositions.
- Host genetics: Guinea pig models may not fully recapitulate human immune responses to tick saliva proteins.
- Duration of immunity: mRNA vaccines may require repeat dosing; durability of anti-tick immunity is unknown.
This is the most radical mechanism on the list. Humans and other catarrhine primates (Old World monkeys and apes) lost functional GGTA1 — the gene encoding α-1,3-galactosyltransferase — approximately 20–28 million years ago, as established by Galili and Swanson's landmark 1991 PNAS paper. The inactivation occurred in both apes and Old World monkeys, likely driven by selection pressure from pathogens (bacteria, parasites, viruses) displaying α-gal epitopes — losing the gene eliminated the surface target while enabling production of anti-Gal antibodies as an immune weapon.
The consequence: the moment GGTA1 was silenced, α-gal became non-self to catarrhines. The anti-Gal antibody population (~1% of all B cells produce some form of anti-Gal) arose because gut microbiota expressing α-gal continuously stimulate the immune system. In AGS patients, this natural IgG/IgM anti-Gal response has "gone wrong" by adding an IgE component.
The speculative cure: if a gene therapy vector (AAV, LNP-mRNA, or CRISPR knock-in) reintroduced functional GGTA1 into a patient's somatic cells — specifically to cells involved in immune tolerance (thymic epithelium, dendritic cells, liver cells) — α-gal would now be expressed as a self-antigen. Central and peripheral tolerance mechanisms would recognize it as self, delete anti-Gal T and B cell clones, and the allergic response would become biologically impossible.
This is not pure fantasy. Mouse studies of tolerance to α-gal epitopes from Galili's 2023 Frontiers in Molecular Biosciences review demonstrated that prolonged (2–4 weeks) in vivo exposure of anti-Gal B cells to α-gal epitopes on transplanted wild-type hearts resulted in durable, transferable immune tolerance — naive anti-Gal B cells emerging from bone marrow treated the α-gal epitopes as self and were tolerized. Most strikingly, this tolerance was demonstrated to persist >100 days and could be re-transferred to secondary recipients, implying a true self-tolerance program was established. In a separate proof-of-concept, autologous lymphocytes engineered to express α-gal via transduction of the α-1,3-galactosyltransferase gene could induce corresponding tolerance in transplant recipients.
The GalSafe pig (Revivicor/United Therapeutics) is the inverse experiment in reverse: these GGTA1 knockout pigs, having lost α-gal expression, now spontaneously produce anti-Gal antibodies (because gut bacteria still express α-gal). Revivicor has used these pigs as models for xenotransplantation and, recently, has been supplying their pork to AGS patients who cannot eat regular meat.
eGenesis has taken the opposite direction — engineering pigs with up to 69 genetic edits including GGTA1 knockout plus human gene insertions for immune compatibility in xenotransplantation. Their clinical programs, while focused on organ transplant, have generated detailed knowledge of what happens to the immune system when α-gal expression is altered.
The concept is biologically valid but faces extraordinary barriers:
Hyperacute rejection risk: All humans carry high-titer anti-Gal IgM and IgG antibodies. If GGTA1 is reintroduced into adult cells, those cells would immediately become targets for complement-mediated destruction by the patient's own existing anti-Gal antibodies. The cells expressing α-gal would be recognized as foreign and destroyed before they could induce tolerance — the exact catastrophe that occurs when α-gal-positive pig organs are transplanted into humans. The window between GGTA1 expression and tolerance induction is lethal.
A potential workaround: administer anti-Gal antibody-depleting therapy (e.g., α-gal glycan columns, plasmapheresis) simultaneously with GGTA1 expression, creating a narrow window for tolerance induction. But this is extraordinarily complex.
Selective delivery required: GGTA1 expression in thymic epithelium would be optimal for central tolerance; in peripheral regulatory cells (DCs, liver) for peripheral tolerance. Systemic expression would trigger the hyperacute reaction described above.
Evolutionary tradeoff: The Galili hypothesis holds that anti-Gal IgM and IgG protect against α-gal-expressing pathogens (certain bacteria, Plasmodium malaria, viruses budding from non-primate host cells). Eliminating anti-Gal immunity as a side effect of GGTA1 reintroduction could increase susceptibility to these pathogens. This is a genuine and serious concern documented in the Research Outreach 2023 analysis of the AGS trade-off.
- Hyperacute self-rejection: The most likely immediate outcome of GGTA1 reintroduction in an adult with normal anti-Gal antibody titers.
- Incomplete tolerance induction: Partial GGTA1 expression in some cell lineages but not others could lead to unpredictable, partial immunogenicity.
- Pathogen susceptibility: Loss of protective anti-Gal IgM against malaria and other α-gal-expressing pathogens.
- Cancer biology: α-Gal expression on dividing tumor cells could affect immune surveillance in unknown ways; α-gal on glycoproteins can affect folding, receptor binding, and biological activity.
The "old friends" or hygiene hypothesis framework holds that chronic low-level helminth (parasitic worm) colonization in pre-industrial humans drove a sustained immunoregulatory state — high Treg numbers, high IL-10, high IL-35, and an isotype profile dominated by IgG4 rather than IgE. In helminth-naive populations, Th2 responses go unchecked; allergen exposure leads to IgE instead of tolerogenic IgG4. Helminths suppress this via polyclonal B cell stimulation toward IgG4, Treg expansion, and direct suppression of Th2 effector pathways.
For AGS specifically, the mechanism would work in two steps: (1) helminth infection establishes a broad immunoregulatory state — high Tregs, IL-10, TGF-β — that suppresses existing Th2/IgE responses globally; (2) within this suppressive environment, continued antigen exposure (red meat ingestion, even tick saliva α-gal) would be processed tolerogenically rather than as an IgE trigger, driving class switch to IgG4. The IgG4 anti-α-gal antibodies would competitively block IgE binding sites on mast cells and basophils, reducing reactivity. A key insight from the allergy literature: non-allergic individuals with high natural anti-Gal IgG levels show significantly higher α-gal-specific IgG4 than allergic individuals, who show high IgG1 and IgG3 — the protective isotype distribution seen in helminth-endemic populations per the 2016 Allergy study on IgG subclasses in meat allergy.
Hodžić et al. (2020) have specifically proposed that helminth infections in humans may modulate the immunological consequences of tick bites — populations with helminth-high microbiome show different tick bite immune responses, with lower incidence of AGS. This is an observational/theoretical framework, not a clinical study, but the evolutionary logic is compelling.
Necator americanus (human hookworm) has been tested in multiple inflammatory and allergic disease clinical trials. A Frontiers in Allergy 2022 review documented robust hookworm-induced immunomodulation: increases in Treg numbers and IL-10, reduction in eosinophilia, IgE class-switching suppression, and IgG4 induction. A Phase 1 trial of hookworm in celiac disease showed reduced IFN-γ and IL-17 cytokine responses to gluten in duodenal biopsies, though without clinical symptom benefit — an instructive failure that demonstrates immune modulation is necessary but may not be sufficient.
Trichuris suis ova (TSO) (pig whipworm): Tested in Crohn's disease and MS, TSO colonizes only transiently in humans (species-specific), avoiding the risks of chronic infection. Results have been mixed in IBD trials but immunological modulation is consistently demonstrated.
Malaghan Institute (New Zealand) is expanding hookworm therapy programs to include allergic diseases (asthma, allergic rhinitis, eosinophilic esophagitis) with multiple active trials as of 2020.
Tranquility Bio (formerly Coronado Biosciences spinoff) is developing controlled helminth infection as a platform therapy. No active AGS-specific program.
The main barriers are not biological but clinical: controlled helminth infection is inherently difficult to dose, produces uncomfortable side effects during initial colonization (dermatitis, GI symptoms for weeks 4–12), and has a regulatory path that is extremely complex. Phase 2 trials in specific allergic diseases have generally shown immunological activity without consistent clinical benefit — possibly because the dose, timing, and disease context weren't optimized. An AGS-specific trial would need to confirm that alpha-gal IgE levels decline faster in helminth-infected, tick-exposed patients than in tick-avoidance-alone controls.
The most pragmatic near-term version: identify the specific helminth-derived immunomodulatory molecules (omega-1, FABP, cysteine proteases) responsible for IgG4 class switching and Treg induction, and develop synthetic versions as injectable biologics. This drug-like approach would deliver the tolerogenic signal without the actual parasites.
- Inconsistent clinical benefit: Multiple Phase 2 trials have shown immunological changes without translating to clinical endpoints.
- Temporary colonization: Necator americanus provides sustained effects only during active infection (months to years); discontinuation may lead to rebound.
- Side effects: The "therapeutic window" of helminth dosing is narrow; too few worms are ineffective, too many cause pathology.
- Carbohydrate allergen specificity: Most helminth immunomodulation is polyclonal and broad, not targeted to the α-gal-specific IgE pathway. IgE suppression may be general rather than AGS-specific, and the α-gal allergy may partially persist.
HSCT is the most extreme available intervention: myeloablation (whole-body irradiation or chemotherapy conditioning) destroys the patient's entire hematopoietic system — including virtually all IgE-producing B cells, memory T cells, and bone marrow progenitors. Replacement with donor hematopoietic stem cells reconstitutes a new immune system, derived from a donor who is (presumably) not sensitized to α-gal, and without AGS. The reconstituted immune system would encounter α-gal as it is encountered by all non-sensitized humans — through gut bacteria and diet — and should develop the normal non-IgE response (IgG, IgM) to it.
A 2020 Allergy study prospectively investigated 50 donor-recipient pairs undergoing allogeneic HSCT and found that 94% of allergen-specific IgE responses were lost within two years post-transplantation when donors were non-allergic. This is the largest prospective dataset demonstrating HSCT-mediated food allergy resolution. The Frontiers in Allergy 2022 review described HSCT as "the most dramatic impact on allergy in humans — a total factory reset of the immune system."
The same review noted a critical mechanistic insight: the rapid loss of allergen-specific IgE after myeloablation (faster than expected if long-lived plasma cells maintained it) implies that short-lived, rapidly replenishing plasma cells — not long-lived plasma cells — are the primary maintainers of food allergy IgE. This is a key target insight for any curative approach.
The DOCK8 deficiency case series from NIH was more cautionary: in 12 patients, food allergies persisted after HSCT in several cases, even with 100% peripheral blood donor chimerism. The incomplete bone marrow chimerism in many patients left residual host-derived IgE-producing plasma cells. However, the overall trend toward IgE reduction was consistent.
A peanut sensitization case was documented as resolving after HSCT for hematologic malignancy (ScienceDirect 2020 abstract).
HSCT is the most technically mature curative option, and it clearly works for allergy in the right donor-recipient pairing. The barrier is entirely risk-benefit: current HSCT mortality is 5–20% depending on conditioning regimen and donor match; significant morbidity from graft-versus-host disease (GVHD) is common. These risks are appropriate for malignancies or severe immunodeficiency but not for a condition managed by dietary avoidance.
However, for patients with extremely severe AGS who also require HSCT for an oncologic or immunological indication, the allergy-curing effect would be a meaningful secondary benefit. More speculatively, as reduced-intensity conditioning protocols mature and GVHD prevention improves, the risk-benefit calculation might shift for severe AGS cases. The emerging data on autologous HSCT (no GVHD risk) for autoimmune diseases — where the patient's own stem cells are harvested, the immune system ablated, and the same cells reinfused — suggests a potentially lower-risk path. Autologous HSCT followed by antigen-specific tolerogenic re-education could be a future "immune reset" protocol.
- Mortality and morbidity: Current risk is unacceptable for AGS as an indication.
- Incomplete chimerism: Residual host IgE plasma cells in protected bone marrow niches can reconstitute the allergy.
- GVHD: In allogeneic HSCT, graft-versus-host disease can itself trigger new allergic responses or worsen existing ones.
- Re-sensitization: After transplant, new immune system can re-sensitize to α-gal if tick exposure occurs.
An intermediate between CAR-Treg therapy (Mechanism 1) and polyclonal Treg expansion: take a patient's own regulatory T cells, expand them ex vivo using antigen-specific stimulation with α-gal-conjugated antigen presenting cells, then reinfuse. This generates a population of α-gal-experienced Tregs that, when returned to the body, specifically suppress responses in the α-gal antigenic environment — gut, mucosa, dermis.
Unlike CAR-Treg, this approach uses the natural Treg T cell receptor rather than an engineered CAR, which means it has the full range of natural regulatory outputs (IL-10, TGF-β, contact suppression) rather than the narrower CAR-mediated signals. The challenge is that carbohydrate antigens do not directly stimulate T cells (carbohydrates are not MHC-presented); the expansion must use protein carriers conjugated to α-gal that present both the carbohydrate epitope (for IgE pathway targeting) and T cell-stimulatory peptide epitopes.
Sonoma Biotherapeutics focuses on engineered Tregs with cytokine receptor modifications for durability (self-sufficient IL-2 signaling) and has reported Phase 1 data in refractory rheumatoid arthritis at ACR 2025. Their platform is disease-agnostic in principle.
Tregenix (earlier-stage) aims at ex vivo expanded antigen-specific Tregs for autoimmunity.
The scientific question for AGS specifically is: can α-gal-experienced Tregs suppress IgE responses in patients who already have high-titer IgE? The existing OIT literature is discouraging — Treg expansion during OIT in clinical trials has been inconsistent, and some studies show Treg frequency decreasing even when successful tolerance is achieved. The 2025 Frontiers review notes that allergen-specific Tregs in food allergy are scarce in peripheral blood and predominantly reside in intestinal tissues, making ex vivo expansion technically demanding.
- Same as Mechanism 1, plus the additional challenge that natural TCR-based Treg specificity for carbohydrate antigens is poorly defined.
- Treg plasticity in Th2-inflammatory environments — risk of reprogramming to pathogenic Th2-like cells.
- Manufacturing complexity for autologous products.
A crucial insight from COVID-19 mRNA vaccine immunology: nucleoside-modified mRNA vaccines (using m1Ψ pseudouridine substitution) encode antigen but avoid the pro-inflammatory TLR7 signaling normally induced by unmodified RNA. In conventional vaccination, this innate activation is needed for strong adaptive immunity. But for tolerance induction, it is the enemy — delivering antigen without inflammatory co-stimulation programs T cells toward anergy, exhaustion, or Treg differentiation rather than effector responses.
Several groups have demonstrated that m1Ψ-mRNA encoding autoantigen, delivered in lipid nanoparticles without inflammatory adjuvant, induces antigen-specific tolerance in experimental autoimmune encephalomyelitis (mouse MS model) — without impairing responses to unrelated antigens. A 2025 PMC review on inverse vaccination summarizes this mechanistically: transfected APCs present autoantigen with low co-stimulatory molecule expression, generating Tregs via CTLA-4/PD-1 signaling rather than effector T cells.
For food allergy, a September 2025 Penn Medicine/Cincinnati Children's study demonstrated that allergen-encoding mRNA vaccines (encoding ovomucoid for egg allergy, Arah2 for peanut allergy) prevented anaphylaxis in mouse models with lower IgE, fewer eosinophils, reduced mucus, and protected airways. A concurrent September 2025 PMC publication showed allergen-specific mRNA-LNP vaccination reduced Th2 effectors, increased Th1 and cytotoxic CD8 responses, and reduced IgE in both preventive and established allergy models.
For AGS: an mRNA encoding a fusion protein containing α-gal-conjugated peptide epitopes could, delivered in a non-inflammatory LNP formulation, program tolerance to α-gal. The platform advantage is tremendous: rapid design, scalable production, established manufacturing infrastructure.
Moderna's mRNA-3927 (propionic acidemia), BNT111 (cancer vaccine), and several undisclosed autoimmune programs at both Moderna and BioNTech demonstrate the platform's versatility. Neither company has disclosed an AGS or food allergy tolerogenic program, but both have published on tolerogenic mRNA approaches in their research pipelines.
The mRNA platform is the most technologically mature among "speculative" approaches. The specific application to AGS requires: (1) design of an α-gal carrier protein that generates appropriate T cell epitopes without Th2 bias; (2) demonstration that tolerogenic mRNA-LNP can reduce established IgE (not just prevent sensitization, which the September 2025 data demonstrates); (3) animal testing in the GGTA1 KO pig model; (4) Phase 1 safety. Compared to cell therapies, this is dramatically simpler to manufacture and administer.
- Encoding a carbohydrate allergen: mRNA encodes proteins, not carbohydrates. The approach requires an α-gal-conjugated protein construct or a protein that presents α-gal-like epitopes — a significant biochemical engineering challenge.
- Breaking vs. preventing tolerance: The September 2025 papers showed better prophylactic than therapeutic efficacy. Established IgE allergy with sensitized mast cell populations may need additional intervention beyond T cell re-programming.
- Th1 skewing side effects: Redirecting Th2 responses toward Th1 (as some mRNA approaches do) could theoretically increase Th1-mediated pathology; for AGS specifically, which has unusual Th1 co-activation (IL-4-dependent sensitization but also Th1 cell presence per the GGTA1 KO pig sensitization study), this is a complex immunological landscape.
The most targeted conceivable curative approach: identify the specific B cell clones producing pathogenic IgE anti-α-gal antibodies, and CRISPR-edit their V(D)J heavy chain variable region to eliminate antigen specificity. A 2019 Nature study (PMC) demonstrated that CRISPR-Cas9 homology-directed repair (HDR) can replace the endogenous V(D)J variable region of mature human B cell lines with a defined sequence — introducing HIV broadly neutralizing antibody specificity into cells that previously had unrelated BCR specificities. The strategy is designed to work regardless of which V, D, and J genes were originally assembled.
The AGS angle: the PNAS 2022 study on the structural basis of human anti-α-gal antibody responses found preferential usage of heavy chain germline IGHV3-7 encoding a conserved tryptophan (W33) in the complementarity-determining region among both AGS patients and healthy anti-Gal producers. The W33 motif was critical for α-gal binding across all analyzed antibodies, and introducing W33 into naive IGHV3-23 libraries enabled rapid selection of α-gal binders. This means the pathogenic IgE B cells likely share a structural signature that could theoretically be targeted: identify B cells expressing IGHV3-7 with W33 that have undergone IgE class-switch, harvest and CRISPR-edit them ex vivo to disrupt IGHV3-7 or replace the CDR3 loop, and re-infuse. Alternatively, in vivo delivery of CRISPR to IgE+ B cells (using mRNA-LNP or AAV targeted to B cells) could directly ablate the anti-α-gal BCR.
The concept is sound — B cell receptor reprogramming by CRISPR in primary human B cells was demonstrated in 2019 and expanded. However, the practical barriers are formidable:
- Identifying target clones: Tens of thousands of IgE+ B cells exist; isolating and editing each clone's V(D)J region requires single-cell precision at scale.
- In vivo delivery: LNPs targeting specifically IgE+ B cells in lymph nodes and bone marrow with sufficient efficiency for therapeutic editing does not yet exist.
- Clonal escape: Memory B cell clones not eliminated by editing will persist and can re-expand after re-stimulation by tick bites.
- Base editing safety: High-fidelity base editors still generate off-target edits; the Nature Biotechnology 2026 CHANGE-seq-BE study shows substantially higher off-target activity with ABE8e base editors compared to Cas9 nuclease at matched targets.
- Technically immature for primary B cells at scale.
- Insufficient targeting specificity to distinguish pathogenic IgE anti-α-gal B cells from the broader anti-Gal IgG/IgM pool (since many of the same clones contribute to both).
- Likely to be superseded by simpler mIgE-targeted CAR-T approaches (Mechanism 2) that achieve the same result without cell-by-cell CRISPR editing.
The microbiome is the primary stimulus for baseline anti-Gal IgG/IgM production — gut bacteria expressing α-gal (particularly E. coli O86:B7 and various Enterobacteriaceae) continuously stimulate the immune system. The nature of this stimulation — tolerogenic or activating — is shaped by the microbiome's overall composition. A microbiome dominated by butyrate-producing Clostridia promotes Treg induction and IgA-mediated tolerance; a dysbiotic microbiome with high Proteobacteria or low Firmicutes correlates with allergic sensitization.
A 2020 Frontiers in Immunology study demonstrated that oral administration of E. coli O86:B7 to turkeys reduced lung anti-α-gal IgA, protecting against aspergillosis — showing that microbiome-driven modulation of the anti-Gal immune response is feasible. The implication for AGS: a FMT from a donor with a "tolerogenic" microbiome composition (high Clostridia, high α-gal-expressing bacteria, ideally also helminth-colonized — since helminths modify the gut microbiome toward tolerance) could re-program the systemic immune response to α-gal from IgE toward tolerogenic IgG4.
Animal data are encouraging: FMT from healthy donors protected food allergy-prone mice from sensitization, and FMT from allergic donors transferred the allergy to naive mice — establishing a direct causal role for the microbiome in food allergy susceptibility. A Phase 1 human trial of oral FMT capsules in peanut allergy (Harvard/Rachid group) showed preliminary efficacy signals — increased peanut tolerance thresholds and decreased peanut IgE in some participants.
FMT is available now for C. difficile but remains experimental for allergy. The specific challenge for AGS: the allergy's unique driver (tick bite-induced Th2 inflammation) is not purely microbiome-mediated, so microbiome reset alone may be insufficient. However, a combined approach — FMT + helminth infection + antigen-specific tolerogenic therapy — could be synergistic, with the FMT establishing the immunoregulatory baseline and the specific therapy targeting the IgE pathway directly.
- No confirmed clinical efficacy in IgE food allergy in humans.
- Donor variability: identifying the optimal donor microbiome composition for AGS-specific IgE suppression is poorly understood.
- FMT from helminth-positive donors: helminth carriage in Western donors is extremely rare; obtaining qualified donors with appropriate microbiome composition would be a regulatory and logistical challenge.
A more controlled version of Mechanism 5. Rather than re-introducing GGTA1 systemically (with hyperacute self-rejection risk), engineer a small number of autologous cells (patient-derived dendritic cells, lymphocytes, or liver cells) to express α-gal at their surface, then reinfuse in a controlled setting where circulating anti-Gal antibodies are transiently depleted. The α-gal-expressing cells would migrate to lymphoid tissues and present α-gal as a persistent "self-like" antigen, educating the immune system toward tolerance.
The mouse data from Galili's tolerance studies directly supports this: "autologous lymphocytes engineered to present α-gal epitopes by transduction of the α1,3-galactosyltransferase gene" induced corresponding tolerance in recipients of ABO-incompatible allografts. The tolerance was durable (>100 days, surviving multiple re-immunization challenges) and transferable to secondary recipients via adoptive transfer — proof that the mechanism creates genuine immunological self-tolerance, not just transient suppression.
The technical path is clear in mice but not yet attempted in any primate or human system. Anti-Gal antibody depletion prior to cell infusion is the critical enabling step and adds substantial complexity. Regulatory path is unclear. However, the foundational mouse science is more compelling for this mechanism than for almost any other on this list.
Non-allergic humans normally produce anti-Gal IgG (primarily IgG2, IgG4 in helminth-endemic areas) that constantly recognizes α-gal from gut bacteria and dietary red meat. These IgG antibodies do not trigger mast cell degranulation. In AGS patients, the isotype distribution is pathologically skewed: high IgG1/IgG3 (inflammatory) and low IgG4 (blocking/tolerogenic), plus the pathogenic IgE, per the 2016 Allergy study. Non-allergic individuals have significantly higher α-gal-specific IgG4.
The curative hypothesis: administer α-gal in a non-inflammatory adjuvant context that promotes IgG4 switching (IL-10, TGF-β driven) — essentially oral immunotherapy for alpha-gal but with a class-switch-inducing protocol. The existing anti-Gal IgG would be re-directed from IgG1/IgG3 toward IgG4, which acts as a blocking antibody, outcompeting IgE for α-gal binding on mast cells/basophils while preventing complement activation. The helminth-derived approach (Mechanism 6) is one way to achieve this; repeated mucosal α-gal exposure with regulatory adjuvants (IL-10, TGF-β mimetics, rapamycin) is another.
Importantly, this approach acknowledges and works with the baseline anti-Gal IgG response rather than trying to eliminate it. The target state — abundant anti-Gal IgG4 with minimal IgE — is already found in clinically tolerant individuals.
The IgG4 class switch mechanism is well understood and the target state is well defined. The challenge is that directing class switching in established allergy, where IgE memory is already set, requires both suppression of the ongoing IgE response and induction of competing IgG4. Allergen-specific immunotherapy with sublingual or oral α-gal does induce IgG4 in some protocols, and this pathway may represent the most biologically elegant and achievable near-term curative approach — essentially an optimized, rapamycin-enhanced OIT for α-gal.
| Rank | Mechanism | Timeline | Readiness Level | Key Blocker |
|---|---|---|---|---|
| 1 | Anti-tick mRNA vaccine (prevention of re-sensitization) | 5–10 years | Preclinical efficacy proven; Phase 1 in planning | Species specificity, does not treat existing allergy |
| 2 | IgE-specific B-cell depletion (mIgE CAR-T/anti-CεmX) | 7–12 years | Target validated, CAR-T platforms maturing | Long-lived plasma cell escape; no AGS-specific program yet |
| 3 | mRNA tolerogenic vaccine (non-inflammatory LNP-mRNA) | 7–12 years | Platform proven for other antigens; food allergy preclinical data strong (Sept 2025) | Encoding carbohydrate antigen in mRNA; established allergy harder than prevention |
| 4 | Tolerogenic nanoparticle vaccine (Topas/SVP-Rapa) | 8–15 years | Clinical proof-of-concept in celiac disease (2024–2025) | Carbohydrate conjugation chemistry; AGS-specific Phase 1 not yet started |
| 5 | IgG4 class-switch forced via tolerogenic adjuvant + alpha-gal | 10–15 years | Strong biological rationale; OIT-adjacent | Clinical protocol undefined; requires both IgE suppression and IgG4 induction |
| 6 | CAR-Treg (allergen-specific) | 10–15 years | Treg clinical programs progressing; no allergen-specific CAR design | Carbohydrate CAR design unsolved; manufacturing cost |
| 7 | Helminth therapy (Necator americanus, structured course) | 10–20 years | Phase 1/2 in allergic disease ongoing; AGS-specific data absent | Inconsistent clinical translation; side effects; regulatory complexity |
| 8 | Engineered autologous Tregs (ex vivo expanded) | 12–18 years | Sonoma/Quell platform maturing; food allergy-specific absent | Carbohydrate Treg specificity poorly defined |
| 9 | HSCT from non-AGS donor | Available now (wrong risk profile) | 94% food allergy IgE loss documented post-HSCT | 5–20% procedure mortality; unacceptable for AGS alone |
| 10 | FMT / microbiome reset | 10–20 years | Preclinical data promising; Phase 1 in peanut allergy ongoing | Not allergy-specific; helminth-positive donor unavailable |
| 11 | Engineered alpha-gal-expressing autologous cells | 15–20 years | Mouse proof-of-concept (Galili lab); no human data | Anti-Gal depletion required; primate data absent |
| 12 | CRISPR B cell editing | 20+ years | Proof-of-concept in B cell lines only | Scale, specificity, in vivo delivery unsolved |
| 13 | GGTA1 gene therapy (re-introduce GGTA1 as self-antigen) | 20+ years (possibly never) | Deep mouse tolerance data (Galili); no human path defined | Hyperacute self-rejection; pathogen susceptibility trade-off |
The most important insight from the natural history data is that AGS is not biologically permanent. Alpha-gal IgE wanes at ~27%/year with tick avoidance alone; ~12% of patients achieve full remission over 5+ years. This tells us that the pathogenic IgE-producing cell population — likely short-lived plasma cells rather than long-lived bone marrow residents — is continuously replenished in the presence of tick antigen stimulation, and the replenishment pathway can be interrupted. Any curative approach that simultaneously (a) removes or suppresses existing IgE B cells/plasma cells and (b) prevents re-sensitization would achieve a functional cure.
The most plausible near-term clinical trial design: mRNA tolerogenic vaccine for α-gal + anti-tick vaccine, given together to a patient on strict tick avoidance. The tolerogenic mRNA drives T cell tolerance and IgG4 shift; the anti-tick vaccine prevents any future re-sensitization; tick avoidance allows existing IgE to wane naturally. This tri-pronged approach leverages three independently developing platform technologies and does not require any novel biology — just combination of existing programs aimed at a single disease.
The biggest scientific unknown across all mechanisms is the long-lived plasma cell question: do AGS patients have bone marrow-resident IgE plasma cells that will continuously secrete IgE regardless of what is done to B cells or T cells upstream? The HSCT data suggests these cells are not the primary AGS maintenance mechanism (IgE drops quickly after HSCT even before full bone marrow reconstitution), but the DOCK8 persistence data suggests they may exist in a subset of patients. Clarifying this will be critical for any curative program.
| Entity | Focus | Status |
|---|---|---|
| Topas Therapeutics | Liver-targeting tolerogenic nanoparticles; celiac Phase 2a complete | Phase 2a POC; AGS application possible |
| Quell Therapeutics | CAR-Treg; LIBERATE (transplant) + CHILL (RA/SSc) | Phase 1/2 active |
| Sangamo Therapeutics | CAR-Treg; STEADFAST kidney transplant | Phase 1/2 active |
| Sonoma Biotherapeutics | Engineered Tregs; RA Phase 1 | Phase 1 interim data Oct 2025 |
| Cabaletta Bio | Anti-CD19 CAR-T; B cell depletion without preconditioning | Phase 1/2 RESET program |
| IgGenix | Alpha-gal-specific mAb discovery; peanut Phase 1 ACCELERATE | Characterizing AGS antibody repertoire |
| Revivicor/United Therapeutics | GalSafe pigs; GGTA1 KO xenotransplant | Commercial food + transplant programs |
| Yale/Fikrig lab | 19ISP anti-tick mRNA vaccine | Preclinical; licensing discussions |
| University of Michigan (Shea lab) | PLG nanoparticle tolerogenic immunotherapy for AGS | Preclinical (2024) |
| Malaghan Institute | Hookworm therapy for allergic disease | Phase 1/2 trials expanding |
| COUR Pharmaceuticals | Tolerogenic nanoparticles; CNP-201 peanut Phase 1/2 | Phase 1/2 recruiting |
| Food Allergy Fund / Penn Medicine | Allergen-mRNA vaccine for food allergy (preclinical) | Preclinical Sept 2025 |
All citations include full URLs. Key primary literature:
- Galili & Swanson 1991 PNAS (GGTA1 inactivation): https://pnas.org/doi/full/10.1073/pnas.88.16.7401
- Commins et al. natural history (IgE decline): https://pmc.ncbi.nlm.nih.gov/articles/PMC6980488/
- Fikrig 19ISP anti-tick vaccine: https://www.science.org/doi/10.1126/scitranslmed.abj9827
- Hart IscREAM 2025: https://www.science.org/doi/10.1126/scitranslmed.ads9207
- Galili tolerance induction review 2023: https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1209974/full
- Topas Phase 2a celiac POC: https://topas-therapeutics.com/topas-therapeutics-tpm502-achieves-gluten-specific-tolerance-induction-positive-safety-profile-in-phase-2a-trial-in-celiac-disease-patients/
- mIgE CAR-T for atopic allergy: https://pmc.ncbi.nlm.nih.gov/articles/PMC10759977/
- MEDI4212 anti-IgE B cell depletion: https://pmc.ncbi.nlm.nih.gov/articles/PMC4856805/
- IgG subclasses in alpha-gal allergy: https://pmc.ncbi.nlm.nih.gov/articles/PMC5244683/
- CRISPR B cell BCR reprogramming: https://pmc.ncbi.nlm.nih.gov/articles/PMC6355199/
- IGHV3-7 W33 motif in anti-α-gal: https://www.pnas.org/doi/10.1073/pnas.2123212119
- HSCT and 94% IgE loss: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14278
- GGTA1 KO pig AGS model: https://pmc.ncbi.nlm.nih.gov/articles/PMC10925645/
- FMT in allergic disease: https://pmc.ncbi.nlm.nih.gov/articles/PMC11612733/
- mRNA-LNP allergen vaccine preclinical (Penn, 2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12578384/
- Inverse vaccination for autoimmune disease: https://pmc.ncbi.nlm.nih.gov/articles/PMC12293635/
- U-Michigan alpha-gal nanoparticles 2024: https://www.frontiersin.org/journals/allergy/articles/10.3389/falgy.2024.1437523/full
- Sangamo TX200 STEADFAST update 2025: https://www.sangamo.com/wp-content/uploads/2025/08/WTC-2025_SGMO_TX200-Clinical-Update_6August2025.pdf
- Quell QEL-001 LIBERATE clinical data: https://clinicaltrials.gov/study/NCT05234190
- Quell CHILL trial QEL-005: https://www.quell-tx.com/news/quell-therapeutics-initiates-chill-phase-1-2-trial
- Cabaletta B cell depletion without preconditioning: https://www.fiercebiotech.com/biotech/cabalettas-car-t-therapy-wipes-out-b-cells-small-autoimmune-trial-without-preconditioning
- IgGenix alpha-gal mAb discovery: https://iggenix.com/pressreleases/iggenix-to-present-alpha-gal-syndrome-monoclonal-antibody-discovery-at-2025-aaaai-wao-joint-congress/
- Selecta SVP rapamycin peanut/celiac: https://www.biospace.com/selecta-presents-preclinical-data-regarding-svp-enabled-peanut-allergy-therapeutic-vaccine-and-celiac-disease-treatment
- Hookworm human therapy review: https://pmc.ncbi.nlm.nih.gov/articles/PMC4374592/
- Food allergy resolution post-HSCT Frontiers 2022: https://www.frontiersin.org/journals/allergy/articles/10.3389/falgy.2022.826623/full